Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle A Fanale

Showing results (11-20 of 83) with videos related to

Pageof 9
Sort By:
Clinical Breast Cancer|November 10, 2005
Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancyMichelle A Fanale, Anne R Uyei, Richard L Theriault, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin LymphomaPaolo Strati, Shabnum Patel, Loretta Nastoupil, et al.
Hematological Oncology|September 14, 2018
Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotinDai Chihara, Shannon Wong, Tatyana Feldman, et al.
British Journal of Haematology|August 10, 2016
Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS InvolvementDai Chihara, Nathan H Fowler, Yasuhiro Oki, et al.
The Oncologist|March 27, 2023
Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and ChemotherapyJohn M Burke, Nicholas Liu, Kristina S Yu, et al.
British Journal of Haematology|December 20, 2015
Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicityChan Y Cheah, Loretta J Nastoupil, Peter McLaughlin, et al.
Annals of Hematology|January 9, 2019
Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?Dai Chihara, Yasuhiro Oki, Michelle A Fanale, et al.
Future Oncology (London, England)|September 4, 2023
Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma: the real-world US CONNECT studyAndrew M Evens, Kristina S Yu, Nicholas Liu, et al.
British Journal of Haematology|July 7, 2018
Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvementDai Chihara, Yasuhiro Oki, Michelle A Fanale, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 2, 2023
The impact of classic Hodgkin lymphoma on informal caregivers: results from the CONNECT cross-sectional surveyDarcy R Flora, Andrew M Evens, Nicholas Liu, et al.
Pageof 9

Showing results (11-20 of 83) with videos related to

Sort By:
Pageof 9
Clinical Breast Cancer|November 10, 2005
Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancyMichelle A Fanale, Anne R Uyei, Richard L Theriault, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin LymphomaPaolo Strati, Shabnum Patel, Loretta Nastoupil, et al.
Hematological Oncology|September 14, 2018
Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotinDai Chihara, Shannon Wong, Tatyana Feldman, et al.
British Journal of Haematology|August 10, 2016
Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS InvolvementDai Chihara, Nathan H Fowler, Yasuhiro Oki, et al.
The Oncologist|March 27, 2023
Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and ChemotherapyJohn M Burke, Nicholas Liu, Kristina S Yu, et al.
British Journal of Haematology|December 20, 2015
Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicityChan Y Cheah, Loretta J Nastoupil, Peter McLaughlin, et al.
Annals of Hematology|January 9, 2019
Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?Dai Chihara, Yasuhiro Oki, Michelle A Fanale, et al.
Future Oncology (London, England)|September 4, 2023
Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma: the real-world US CONNECT studyAndrew M Evens, Kristina S Yu, Nicholas Liu, et al.
British Journal of Haematology|July 7, 2018
Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvementDai Chihara, Yasuhiro Oki, Michelle A Fanale, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 2, 2023
The impact of classic Hodgkin lymphoma on informal caregivers: results from the CONNECT cross-sectional surveyDarcy R Flora, Andrew M Evens, Nicholas Liu, et al.
Pageof 9